ReviewWiley interdisciplinary reviews. Systems biology and medicine
Pharmacogenomics: a systems approach.
Review in Wiley interdisciplinary reviews. Systems biology and medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 63 citations in OpenAlex.
- Enhanced Untargeted Metabolomics Based on High-Resolution Mass Spectrometry Reveals Global Rewiring Due to Mitochondrial Dysfunction in Yeast.International journal of molecular sciences · 2026Article
- Pharmacogenomic variation and chemotherapy-related toxicity profiles in pediatric patients with cancer in Tanzania: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation.Journal of clinical medicine · 2023Review
- COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics.Nucleic acids research · 2021Article
- A Systems Biology Approach for Personalized Medicine in Refractory Epilepsy.International journal of molecular sciences · 2019Review
- Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks.Scientific reports · 2019Article
- Application of Radiomics for Personalized Treatment of Cancer Patients.Cancer management and research · 2019Review
- Use of Pharmacogenetic Drugs by the Dutch Population.Frontiers in genetics · 2019Article
- DrugBank 5.0: a major update to the DrugBank database for 2018.Nucleic acids research · 2018Article
- Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes.Frontiers in pharmacology · 2018Article
- System pharmacogenomics application in infectious diseases.Briefings in functional genomics · 2017Review
- Metabolomics Applications in Precision Medicine: An Oncological Perspective.Current topics in medicinal chemistry · 2017Review
- Ethiopian health care professionals' knowledge, attitude, and interests toward pharmacogenomics.Pharmacogenomics and personalized medicine · 2017Article
- DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Oncotarget · 2016Review
- Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility.World journal of diabetes · 2014Review
- Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2014Article
- Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Pharmacogenomics · 2013Review
- A Framework of Knowledge Integration and Discovery for Supporting Pharmacogenomics Target Predication of Adverse Drug Events: A Case Study of Drug-Induced Long QT Syndrome.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2013Article
- Accounting for receptor flexibility and enhanced sampling methods in computer-aided drug design.Chemical biology & drug design · 2013Review
- Time-related patient data retrieval for the case studies from the pharmacogenomics research network.Journal of medical systems · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Pharmacogenetics and pharmacogenomics involve the study of the role of inheritance in individual variation in drug response, a phenotype that varies from potentially life-threatening adverse drug reactions to equally serious lack of therapeutic efficacy. Pharmacogenetics-pharmacogenomics represents a major component of the movement to 'individualized medicine'. Pharmacogenetic studies originally focused on monogenic traits, often involving genetic variation in drug metabolism. However, contemporary studies increasingly involve entire 'pathways' that include both pharmacokinetics (PKs)--factors that influence the concentration of a drug reaching its target(s)--and pharmacodynamics (PDs), factors associated with the drug target(s), as well as genome-wide approaches. The convergence of advances in pharmacogenetics with rapid developments in human genomics has resulted in the evolution of pharmacogenetics into pharmacogenomics. At the same time, studies of drug response are expanding beyond genomics to encompass pharmacotranscriptomics and pharmacometabolomics to become a systems-based discipline. This discipline is also increasingly moving across the 'translational interface' into the clinic and is being incorporated into the drug development process and governmental regulation of that process. The article will provide an overview of the development of pharmacogenetics-pharmacogenomics, the scientific advances that have contributed to the continuing evolution of this discipline, the incorporation of transcriptomic and metabolomic data into attempts to understand and predict variation in drug response phenotypes as well as challenges associated with the 'translation' of this important aspect of biomedical science into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.